site stats

Griffin nct02874742

WebDec 12, 2024 · RVd followed by high-dose therapy (HDT), autologous stem cell transplant (ASCT), and consolidation is a SoC regimen for US pts with NDMM. This phase 2, randomized study (GRIFFIN; NCT02874742) evaluated DARA plus RVd (D-RVd) in ASCT-eligible NDMM pts. A 16-pt safety run-in showed no safety concerns. WebThe phase II GRIFFIN study evaluated whether the addition of daratumumab to VRd, a monoclonal CD38 antibody, followed by ASCT, could further enhance the depth of response in newly diagnosed MM. ... (OS) in NDMM patients undergoing autologous stem cell transplant (ASCT). The phase II GRIFFIN study (MMY2004, NCT02874742) evaluated …

New Clinical and Real-World Data Support Use of …

WebFeb 24, 2024 · During the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, Jacob Laubach 1 presented an update of the phase II GRIFFIN trial … WebJun 13, 2024 · “The optimal daratumumab-containing maintenance regimen remains to be determined,” Moreau said. “We looked forward to the results of ongoing trials such as … dickinson ck212tp 12ga shotgun https://jackiedennis.com

New DARZALEX® (daratumumab) Data from GRIFFIN …

WebJan 12, 2024 · (different to GRIFFIN [NCT02874742], PERSEUS [NCT03710603], CEPHEUS [NCT03652064], or other trials). ATLAS is a key trial suggesting that maintenance approaches with more than one drug, including lenalidomide, should be … WebSep 13, 2024 · The frequency of daratumumab dosing every 4 weeks of is currently being investigated in the phase 2 GRIFFIN study (NCT02874742) and the phase 3 PERSEUS (NCT03710603), AURIGA (NCT03901963), … WebNov 5, 2024 · The phase 2 randomized GRIFFIN study (NCT02874742) evaluates frontline DARA in combination with lenalidomide, bortezomib, and dexamethasone (D-RVd) in transplant-eligible NDMM. In the primary analysis, ... In GRIFFIN, 93.7% of D-RVd pts and 98.8% of RVd pts reached the minimum institutional CD34 + threshold to perform a … dickinson clan

Paper: Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and …

Category:Paper: Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and …

Tags:Griffin nct02874742

Griffin nct02874742

New DARZALEX® (daratumumab) Data from GRIFFIN Study Show …

WebFeb 19, 2024 · This study was registered at www.clinicaltrials.gov as #NCT02874742. Subjects: Clinical Trials and Observations, Lymphoid Neoplasia, Stimulus Report. ... (N = 16) of GRIFFIN. (A) Response rates over time are shown for the response-evaluable population (n = 16). (B) MRD-negativity rates over time are shown for the intent-to-treat … WebIntroduction: DARA, a human IgGκ monoclonal antibody targeting CD38, is approved as monotherapy and in combination with standard-of-care regimens for relapsed/refractory multiple myeloma and NDMM.In the primary analysis of the phase 2 GRIFFIN study (NCT02874742) in patients with transplant-eligible NDMM, DARA plus RVd (D-RVd) …

Griffin nct02874742

Did you know?

WebThe phase II GRIFFIN study (MMY2004, NCT02874742) investigated the use of daratumumab (dara) in combination with bortezomib (V), lenalidomide (R), and dexamethasone (d; dara-VRd) in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for high-dose chemotherapy and autologous stem cell transplant … WebDec 7, 2024 · About the GRIFFIN Study 4 The Phase 2 GRIFFIN ( NCT02874742 ) study has enrolled and treated more than 200 adults ages 18-70 years with NDMM and who …

WebJun 11, 2024 · Also, I shed light on some new studies; one of them is the GRIFFIN study [NCT02874742] that builds on the old VRd [bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone] paradigm that was developed initially by Paul G. Richardson, MD, and colleagues at the Dana-Farber Cancer Institute. The GRIFFIN study adds daratumumab … WebOct 9, 2024 · When Michelle Castillo was found hanging from a showerhead in her Ashburn, Virginia, home with an electrical cord around her neck, her family was …

WebSep 15, 2024 · In the phase II GRIFFIN study (NCT02874742), investigators randomized patients with transplant-eligible multiple myeloma 1:1 to receive VRd with or without daratumumab. Patients received 4 ... WebDec 11, 2024 · About the GRIFFIN Study The Phase 2 GRIFFIN (NCT02874742) study evaluated the investigational regimen of DARZALEX ® in combination with VRd and …

WebAug 20, 2024 · This trial was registered at www.clinicaltrials.gov as #NCT02874742. Subjects: Clinical Trials and Observations, Lymphoid …

WebNov 5, 2024 · Introduction: DARA, a human IgGκ monoclonal antibody targeting CD38, is approved as monotherapy and in combination with standard-of-care regimens for relapsed/refractory multiple myeloma and … citra 1144 downloadWebAug 27, 2024 · The Phase 2 GRIFFIN (NCT02874742) study evaluated the investigational regimen of DARZALEX ® in combination with RVd and enrolled and treated more than … dickinson clarke forumWebDec 12, 2024 · RVd followed by high-dose therapy (HDT), autologous stem cell transplant (ASCT), and consolidation is a SoC regimen for US pts with NDMM. This phase 2, … citq numberWebOct 18, 2024 · ASHBURN, VA — A fatal crash along Route 267 in Loudoun County went undiscovered for nearly seven hours on Sunday, according to Virginia State Police. The … dickinson classifieds ndcit quarterly reportWebApr 13, 2024 · The phase 2 GRIFFIN study (ClinicalTrials.gov Identifier: NCT02874742) evaluated the addition of the anti-CD38 monoclonal antibody daratumumab to RVd (D-RVd) induction and consolidation with ... cit programs for campsWebDaratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study Br J Haematol . 2024 Nov;199(3):355-365. doi: 10.1111/bjh.18432. dickinson classified ads facebook